Vasoplegia Clinical Trial
Official title:
Pilot Study for Determining the Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery
This is a prospective pilot study in which the effects of ascorbic acid administration are investigated in adult patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass (CPB). Ascorbic acid (Vitamin C) is an essential cofactor in the biosynthesis of catecholamines, and critically ill patients are known to be ascorbate-deficient. In addition, cardiopulmonary bypass (CPB) decreases ascorbic acid concentrations. Cardiac vasoplegia is the loss of vascular tone despite adequate volume status and cardiac output, occurring commonly in patients after CPB. This necessitates the administration of vasopressors and alternative agents which can have deleterious effects. The administration of ascorbic acid to cardiac surgical patients may improve microcirculatory function, enhance endogenous catecholamine levels and decrease the need for exogenous vasopressor support.
1. Specific Aims The investigators aim to determine the feasibility of performing a study that can assess the impact of ascorbic acid administration on the development and severity of cardiac vasoplegia in cardiac surgical patients undergoing procedures at high risk for vasoplegia. Specific Aim 1: Determine the feasibility of administration of high dose intravenous ascorbic acid in the operative and post-operative environments as well as sample size for a prospective, randomized, placebo controlled study. Specific Aim 2: Determine baseline ascorbic acid plasma levels in a small cohort of cardiac surgical patients. Specific Aim 3: Determine the impact of ascorbic acid administration on microvasculature as measured by dark field microscopy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05922982 -
Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04812717 -
Prevention of Low Blood Pressure After Cardiac Surgery in Heart Failure Patients With a Filter Called CytoSorb.
|
N/A | |
Recruiting |
NCT05925348 -
Endotoxinemia and Vasoplegia Following Cardiothoracic Surgery With Cardiopulmonary Bypass (CPB)
|
||
Withdrawn |
NCT03446599 -
Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
|
Phase 2 | |
Recruiting |
NCT02965339 -
Evaluation of the Association Between Pre-existing Endothelial Dysfunction and the Onset of Vasoplegia During Cardiac Surgery With Cardiopulmonary Bypass
|
||
Recruiting |
NCT05058612 -
Midodrine for the Early Liberation of Vasopressor Support in the ICU (LIBERATE Multi-Site)
|
Phase 4 | |
Not yet recruiting |
NCT04301479 -
Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)
|
Phase 3 | |
Recruiting |
NCT03968926 -
Hypotension During Extracorporeal Circulatory Support Indicated for Cardiogenic Shock
|
||
Recruiting |
NCT04901169 -
Angiotensin II in Liver Transplantation
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02825056 -
Postoperative Hemodynamics Comparison After High Spinal Block With or Without Intrathecal Morphine.
|
Early Phase 1 | |
Recruiting |
NCT04964492 -
Assessment of the Hemodynamic Effect of Hydroxocabalamin in Refractory Vasodilatory Shock
|
||
Completed |
NCT03120637 -
Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue
|
Phase 4 | |
Completed |
NCT05199493 -
Reducing Acute Kidney Injury Occurence by Administering Angiotensin II
|
Phase 3 | |
Completed |
NCT05354193 -
Analysis of miRNAs Expression in Vasoplegic Syndrome After On-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT05833828 -
Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery
|